Pfizer halts production at a legacy Hospira plant; China works to offer Indian drugmakers streamlined access; Roivant's Sinovant debuts with 11 assets.
Less than one day after Novartis’ CEO talked up a potential key approval for slow-growing Kisqali, the company has that approval in hand.
Patent litigation and long-dated payer contracts are among the “unacceptable” tactics Gottlieb criticized for stalling biosim competition.
The FDA is eyeing foreign imports to combat “dramatic price hikes” on old, competition-free drugs.
Johnson & Johnson has won FDA approval for Symtuza, a new once-a-day HIV drug, but faces a crowded market that includes Gilead's hot-selling Biktarvy.
Roche touted another win Thursday for Tecentriq. But the way some analysts see things, it may actually be a win for Merck's Keytruda
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug picked up an FDA breakthrough designation in liver cancer.
Even before Pfizer faced Trump's wrath for July price hikes, Novartis decided increasing its own prices wouldn’t be prudent, its CEO said Wednesday.
Novartis, whose CAR-T cancer treatment Kymriah was approved less than a year ago, today it has run into some manufacturing issues.
Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.
